Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
PT Enseval Putera Megatrading Tbk 9-Day RSI Related Terms
ISX:EPMT vs MCK, COR, CAH: 9-Day RSI Comparison
For the Medical Distribution subindustry, PT Enseval Putera Megatrading Tbk's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Enseval Putera Megatrading Tbk 9-Day RSI vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Enseval Putera Megatrading Tbk's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where PT Enseval Putera Megatrading Tbk's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Enseval Putera Megatrading Tbk (ISX:EPMT) has a 9-Day RSI of 51.45 as of Aug. 17, 2026. According to the industry distribution chart, PT Enseval Putera Megatrading Tbk ranks #73 out of 125 companies in the Medical Distribution industry, placing it in the top 58.4%.
Is PT Enseval Putera Megatrading Tbk's 9-Day RSI too high?
PT Enseval Putera Megatrading Tbk's current 9-Day RSI is 51.45. The Medical Distribution industry median 9-Day RSI is 49.50. PT Enseval Putera Megatrading Tbk's value of 51.45 is 3.9% above this industry median. Based on the distribution chart, PT Enseval Putera Megatrading Tbk ranks #73 out of 125 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, PT Enseval Putera Megatrading Tbk has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Enseval Putera Megatrading Tbk's 9-Day RSI compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Enseval Putera Megatrading Tbk ranks #73 out of 125 companies for 9-Day RSI. This places PT Enseval Putera Megatrading Tbk in the lower half of its industry. The industry median 9-Day RSI is 49.50. PT Enseval Putera Megatrading Tbk's value of 51.45 is 3.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Distribution company?
The median 9-Day RSI among Medical Distribution companies is 49.50, based on 125 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Enseval Putera Megatrading Tbk's current 9-Day RSI of 51.45 is 3.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median 9-Day RSI is 49.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Enseval Putera Megatrading Tbk's current 9-Day RSI is 51.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Enseval Putera Megatrading Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Enseval Putera Megatrading Tbk (ISX:EPMT) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp2,677.64, compared to a current price of Rp2,340.00 — trading 12.6% below its estimated fair value. The current 9-Day RSI is 51.45 and 3.9% above the Medical Distribution industry median of 49.50. PT Enseval Putera Megatrading Tbk's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For PT Enseval Putera Megatrading Tbk (ISX:EPMT), the current 9-Day RSI is 51.45 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Enseval Putera Megatrading Tbk (ISX:EPMT) Overvalued in 2026?
Based on GuruFocus' analysis, PT Enseval Putera Megatrading Tbk stock appears to be undervalued.
The current stock price of Rp2,340.00 is trading 12.6% below its estimated GF Value™ of Rp2,677.64.
GuruFocus considers PT Enseval Putera Megatrading Tbk to be Modestly Undervalued.
Key valuation signals for ISX:EPMT:
9-Day RSI: 51.45
GF Value™: Rp2,677.64 vs. price of Rp2,340.00 (12.6% below fair value)
Industry Position: 3.9% above the Medical Distribution median (#73 of 125)
No single metric tells the full story. See the ISX:EPMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Enseval Putera Megatrading Tbk is a general distributor dealing in pharmaceutical products, consumer products, and medical devices. The company also acts as an agent and distributor of consumer goods, prescription medicines, non-prescription medicines, raw materials for the pharmaceutical, medical equipment, including marketing activities, veterinary medicines, cosmetics, and other industries. The company's business segments are Pharmaceuticals which generates maximum revenue; Consumer products, and Others.
87GF Score
Get the complete analysis for ISX:EPMT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:EPMT has been successfully added to your 
